Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients

Gargari, Bahar Naghavi; Behmanesh, Mehrdad; Shirvani-Farsani, Zeinab; Kakhki, Majid Pahlevan; Azimi, Amir Reza

doi:10.1016/j.intimp.2015.06.033

Cited by 41 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, it has been proposed that insufficient levels of vitamin D might be an unknown reason for initiation and augmentation of pain sensitization, its severity and neuromuscular dysfunction in the subjects who suffer from chronic pain; if so, supplementation with this vitamin can be helpful in improving pain. In this regard, any interventional procedure that is thought to blunt these pathways could act as a pain relieving agent . The role of 1,25 (OH)2 D in modifying genetic pathways in the target cells is performed via its nuclear receptor or vitamin D receptor (VDR).…”

Section: Discussionmentioning

confidence: 99%

Serum Vitamin D Status in a Group of Migraine Patients Compared With Healthy Controls: A Case–Control Study

et al. 2018

View full text Add to dashboard Cite

Objective The association between serum vitamin D and migraine is investigated in this research.s Background Although the pathogenesis of migraine headache is not fully understood, the possible role of inflammation and disturbed immune system has been proposed; thus, higher levels of vitamin D might reduce the risk of migraine. However, the results of related studies have been inconclusive. Methods Seventy healthy individuals and 70 age‐ and sex‐matched migraineurs (34 chronic and 36 episodic migraineurs), diagnosed according to the International Headache Society criteria (ICHD‐IIIβ), were recruited. After obtaining baseline data and assessing migraine disability, a 30‐day headache diary was given to the participants. Blood samples were obtained and 25(OH)D serum concentrations were determined using ELISA techniques. Serum 25(OH)D under 20, 20–29, and 30–100 ng/mL were considered deficient, insufficient, and sufficient, respectively. The applied statistical tests for between‐group comparisons include independent‐sample t‐test, chi‐square, and analysis of variance. Multiple regression analysis was also performed to identify the possible risk factors of migraine headache. Results Migraine patients had significantly lower mean (SD) of serum VitD (30 (16) ng/mL) than healthy subjects (43 (19) ng/mL) (P < .001). The number (%) of subjects with VitD deficiency and insufficiency was significantly higher among the migraineurs (36 (53.7%)) than the controls (18 (26.1%)) (P < .0001). A significant negative association between migraine headache and serum VitD was detected in the fully adjusted multiple regression models when comparing the third and the highest serum 25(OH)D quartiles with the lowest (OR = 0.20; 95% CI = 0.05–0.77; OR = 0.17; 95% CI = 0.04–0.64, respectively, P for trend = .009). For each 5 ng/mL increase in serum 25(OH)D, there was a 22% odds decrease in the odds of migraine (OR = 0.78; 95% CI = 0.68–0.90; P = .001). Conclusion We have found that a higher level of serum VitD (between 50 to less than 100 ng/mL) among a sample of the Iranian population is associated with 80–83% lower odds of migraine headache than those with serum 25(OH)D levels below 20 ng/mL. However, there is a need for well‐designed clinical trials to investigate beneficial effects of increased serum 25(OH)D on lower risk of migraine.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Vitamin D Status in a Group of Migraine Patients Compared With Healthy Controls: A Case–Control Study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Moreover, in another study conducted by Isik et al [33], the association between TGF-β1 expression and vitamin D 3 deficiency was assessed in patients who had been referred to Endocrinology and Metabolic Diseases Clinic which resulted in that TGF-β1 was negatively correlated with vitamin D 3 , particularly in patients with lower than 5 ng/ml 25(OH) vitamin D 3 levels. It is interesting to note that a variety of factors could contribute to such inconsistency outcomes as reported in various studies including sample size and various geographical regions, cell types, genetic inheritance in participants and the crucially double-faced or pleiotropic role of IL-27 and TGF-β1 and, in some of studies, polymorphisms in Vitamin D Receptor (VDR) genes [6,13,30,34].…”

Section: Plos Onementioning

confidence: 99%

“…Vitamin D 3 has a probable immune-modulatory effect which, changes the equilibrium between anti-and pro-inflammatory interleukins in favor of anti-inflammatory cytokines. So, the lack of vitamin D 3 is possible to cause inflammatory situations in MS patients [2,4,6].…”

Section: Introductionmentioning

confidence: 99%

The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives

et al. 2020

View full text Add to dashboard Cite

Background & aimsIn our previous study, a Seesaw model was proposed for the fluctuation of crucial anti-(IL-10) and pro-inflammatory (Il-6 & IL-17A) cytokines through vitamin D 3 . In this paper, however, it is intended to extend the mentioned model by assessing the expression mRNA levels of IL-27 and TGF-β1 as well as the changes of plasma levels of IL-27, TGF-β1, IL-17A, IL-10, and IL-6 after treatment by vitamin D 3 . MethodVenous blood samples were drawn from Healthy Participants (HP, n = 25) and First-Degree Relative Participants (FDRP, n = 25) as control groups and Multiple Sclerosis Participants (MSP, n = 25) before and after eight weeks of supplementation with 50000 IU vitamin D 3 . The mRNA expression and plasma concentrations were gauged by using Real-Time PCR and ELISA assay, respectively.

show abstract

“…The researchers concluded that supplementing vitamin D3 did not equate to an increase in lymphocytes with a regulatory phenotype. However, they did find that vitamin D contributed to the preservation of immune homeostasis through prevention of more disturbance in the T cell compartment in the onset of MS. Gargari et al (2015) investigated the effects of vitamin D on the expression level of IL-6 and IL-17A in Peripheral Blood Mononuclear Cells (PBMCs) of patients with MS. Additionally, they carried out a correlation between the gene expression and some clinical features such as serum level vitamin D and the Expanded Disability Status Scale (EDSS). Significant up regulation of IL-6 and IL-17A gene expression was shown under vitamin D treatment.…”

Section: Resultsmentioning

confidence: 99%

“…Five of the studies reviewed reported significant results when high dosages of vitamin D3 were administered (Ashtari et al, 2015;Gargari et al, 2015;Toghianifar et al, 2015;Laursen et al, 2016). These improvements were seen when dosage was set at 50,000 IU and manifested in a decrease of relapse rate; up-regulation of IL-6, IL-10, IL-17; and in increased quality of life.…”

Section: Discussionmentioning

confidence: 99%

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

Steinwart¹,

Duriancik²

2018

American Journal of Immunology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is one of the most widespread disabling autoimmune neurological conditions of adults between the ages of 20 and 40 globally. Medical researchers do not completely understand the possible causes of MS, nor have they determined the rate of progression. A limited number of clinical trials conducted in recent years have explored the link between vitamin D deficiency and MS with vitamin D supplementation as a possible element in the treatment of this disease. The primary goal of this review was to synthesize the evidence regarding the link between vitamin D3 levels and the symptoms of MS. A PubMed search was conducted using keywords Vitamin D, multiple sclerosis, MS, RRMS, prevention, treatment and cause. 1153 articles and sources were found using the key phrase "multiple sclerosis and vitamin D," but these were narrowed to 11 based on publication dates between 2013 and 2018, clinical trials were included, while reviews were excluded and the relevance of the goals to this review. Study designs included experimental clinical trials where pretest/posttest data were presented. Articles were excluded if they were not peer reviewed or only described the method and were awaiting results. Although not all studies found uniform results, the majority of the evidence suggests that high intakes of vitamin D may be associated with improved quality of life through the reduction of certain symptoms of MS. This was especially evident in patients who started the studies with a vitamin D deficiency. It may be too early to prescribe an increase in daily supplementation of vitamin D with the hope of reducing the development of or in the treatment of MS, but recent studies indicate that high doses of vitamin D could decrease the probability of some symptoms of the disease and possibly give favorable results in treatment. Further studies are needed before specific recommendations can be made.

show abstract

Vitamin D supplementation up-regulates IL-6 and IL-17A gene expression in multiple sclerosis patients

Cited by 41 publications

References 32 publications

Serum Vitamin D Status in a Group of Migraine Patients Compared With Healthy Controls: A Case–Control Study

Serum Vitamin D Status in a Group of Migraine Patients Compared With Healthy Controls: A Case–Control Study

The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives

High-Dose Vitamin D3 Intake Is Associated with Decreased Symptoms of Multiple Sclerosis

Contact Info

Product

Resources

About